CSL To Pay $64M To Escape Blood Plasma Antitrust Suit
By Gavin Broady ( October 7, 2013, 2:30 PM EDT) -- Australian medical product giant CSL Ltd. announced Monday that it will pay $64 million to escape a consolidated antitrust class action in which hospital groups claim it took part in a conspiracy to artificially hike the price of plasma-derivative protein therapies....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.